+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 195 Actively Recruiting clinical trials

S

Actively Recruiting

This trial studies neuroendocrine tumors, paraganglioma, pheochromocytoma, and other SSTR-positive tumors that are not currently approved for lutetium therapy called LUTATHERA. It aims to evaluate the effectiveness and safety of a similar treatment called lutetium 177Lu edotreotide or 177Lu-DOTATOC in patients who have these diseases but are outside the standard indications for LUTATHERA. The study focuses on expanding knowledge about this therapys role in controlling disease and managing side effects. Participants receive treatment with 177Lu-DOTATOC given by slow intravenous infusion over 30 minutes using a pump system. The dose depends on patient risk factors those with fewer than two risk factors receive 7.4 GBq per cycle, while those with two or more risk factors receive 5.5 GBq per cycle. Each participant will receive 4 cycles of treatment. Risk factors include kidney impairment, previous toxicities, uncontrolled diabetes or hypertension, prior therapies, and disease burden. During the study, participants will have regular assessments over several months, including scans to measure disease control at 32 months and ongoing monitoring up to 44 months for progression-free survival, overall survival, safety, and quality of life. Researchers will check blood tests, organ function, and side effects. This non-randomized phase 2 study allows patients with measurable or evaluable disease and progressive tumors confirmed by imaging to be included, with follow-up to evaluate response and safety.

Age: 18Years +All GendersPhase 2
2 locations
M

Actively Recruiting

This research aims to investigate adult patients with triple negative B-cell Acute Lymphoblastic Leukemia B-ALL who do not have the most common genetic rearrangements linked to the disease. These patients often have a poor prognosis and lack targeted therapies. The study focuses on understanding the molecular characteristics of this subgroup, especially regarding CRLF2 gene alterations, which are important in both adult and pediatric cases and may influence treatment outcomes. The study is non-interventional and observational, meaning treatment decisions are made by doctors as usual and are not influenced by participation. Patients diagnosed with primary or secondary B-ALL will be enrolled and their blood, bone marrow, and saliva samples collected for detailed biological analysis using various laboratory techniques, including gene sequencing and flow cytometry. Both prospective and retrospective patient groups will be studied over a planned period of 36 months. Participants will provide biological samples and clinical data, which will be recorded in a dedicated database. Researchers will evaluate molecular markers to identify patient subgroups, assess potential biomarkers, and correlate findings with survival outcomes. The study aims to develop a rapid and cost-effective method for identifying these leukemia subtypes, with ongoing monitoring and data collection continuing throughout the three-year study duration.

Age: 18Years +All Genders
3 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.

Age: 18Years +All GendersPhase 1Phase 2
57 locations
S

Actively Recruiting

Researchers are investigating whether MK-1084, a targeted therapy, can treat advanced or metastatic non-squamous non-small cell lung cancer NSCLC with KRAS G12C mutations. This study aims to evaluate the safety of MK-1084 when taken with other treatments and to see how many participants experience tumor shrinkage or disappearance. The trial is a phase 1b2 umbrella study focusing on previously treated participants with this specific lung cancer type. Participants receive MK-1084 combined with either Patritumab deruxtecan HER3-DXd or Sacituzumab tirumotecan Sac-TMT until treatment is stopped due to side effects, adverse events, or investigator decision. An arm with MK-1084 plus Cetuximab was discontinued. MK-1084 is given orally, and the other drugs are administered by intravenous infusion. Rescue medications for nausea and vomiting may be given as needed. Throughout the study, participants undergo evaluations for dose-limiting toxicities, adverse events, and treatment discontinuations due to side effects, monitored up to approximately 63 months. Researchers also assess tumor response rates and progression-free survival. Biomarker analysis is performed using tumor tissue or circulating tumor DNA. The trial follows participants until the study completion date in 2032, with ongoing safety and effectiveness monitoring.

Age: 18Years +All GendersPhase 1Phase 2
29 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations

1-10 of 195

1